Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Synthetic lethality is a cell death mechanism triggered by combined genetic alterations.
• Tumor heterogeneity, understanding interactions, drug resistance, and clinical translation pose significant challenges.
• DNA damage response inhibitors show promise in recent clinical trials for cancer therapy.

Purpose of the Study:

• To review current challenges, developments, and opportunities in synthetic lethality for cancer treatment.
• To explore characterization of synthetic lethal interactions and novel drug development technologies.
• To discuss clinical development and drug resistance mechanisms of synthetic lethality.

Main Methods:

• Literature review of synthetic lethality in cancer therapy.
• Analysis of DNA damage response inhibitors' clinical development.
• Exploration of patient selection strategies for targeted therapies.

Main Results:

• Synthetic lethality presents a complex but potent strategy for cancer treatment.
• DNA damage response inhibitors are advancing with promising clinical trial outcomes.
• Understanding resistance mechanisms is crucial for effective therapeutic application.

Conclusions:

• Synthetic lethality, particularly with DNA damage response inhibitors, holds significant potential for precision oncology.
• Overcoming challenges in interaction discovery and clinical translation is key to realizing its full therapeutic benefit.
• Guiding patient selection is essential for maximizing the efficacy of these targeted agents.